Occupancy of brain dopamine D3 receptors and drug craving: A translational approach

Neuropsychopharmacology

Volumn 38, Issue 2, 2013, Pages 302-312

  Mugnaini, Manolo ^a,e   Iavarone, Laura ^a,d   Cavallini, Palmina ^a,e   Griffante, Cristiana ^a,e   Oliosi, Beatrice ^a,e   Savoia, Chiara ^a,e   Beaver, John ^b,f   Rabiner, Eugenii A ^b,g   Micheli, Fabrizio ^a,h   Heidbreder, Christian ^a,h   Andorn, Anne ^c,i   Merlo Pich, Emilio ^a,j   Bani, Massimo ^a,k  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e Aptuit Inc   (United States)

^f ABBOTT LABORATORIES   (United States)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h RECKITT BENCKISER   (United Kingdom)

ⁱ PFIZER INC   (United States)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k UCB PHARMA   (Belgium)

more..

Author keywords

craving; D3 receptor; drug dependence; nicotine; occupancy; smoking

Indexed keywords

GSK 598809; NICOTINE; PLACEBO;

ADULT; ARTICLE; AUTORADIOGRAPHY; BABOON; BINDING AFFINITY; BRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG SEEKING BEHAVIOR; EX VIVO STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PLACE PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SMOKING;

ADULT; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE ANTAGONISTS; DRUG-SEEKING BEHAVIOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; PAPIO ANUBIS; PROTEIN BINDING; RATS; RECEPTORS, DOPAMINE D3; SMOKING; SMOKING CESSATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84871446904     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.171     Document Type: Article

References (38)

1. Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 48-58.
2. Bedi G, Preston KL, Epstein DH, Heishman SJ, Marrone GF, Shaham Y et al (2011). Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol Psychiatry 69: 708-711.
3. Blendy JA, Strasser A, Walters CL, Perkins KA, Patterson F, Berkowitz R et al (2005). Reduced nicotine reward in obesity: cross-comparison in human and mouse. Psychopharmacology (Berl) 180: 306-315.
4. 11C]-(\+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353-1359.
5. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC (1991). Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203-219.
6. 125I](R)-trans-7-hydroxy-2-[N-propyl-N- (3-iodo-2-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J Pharmacol Exp Ther 268: 935-942.
7. Cox LS, Tiffany ST, Christen AG (2001). Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3: 7-16.
8. Glickstein SB, Desteno DA, Hof PR, Schmauss C (2005). Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 15: 1016-1024.
9. Gross TM, Jarvik ME, Rosenblatt MR (1993). Nicotine abstinence produces content-specific Stroop interference. Psychopharma-cology (Berl) 110: 333-336.
10. Gurevich EV, Joyce JN (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with d2 receptor expressing neurons. Neuropsychopharma-cology 20: 60-80.
11. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D(3) receptor antagonists as pharmacother-apeutics for addictions and related disorders. Ann N Y Acad Sci 1187: 4-34.
12. Hughes JR (2007). Measurement of the effects of abstinence from tobacco: A qualitative review. Psychol Addict Behav 21: 127-137.
13. Kalivas PW, Lalumiere RT, Knackstedt L, Shen H (2009). Glutamate transmission in addiction. Neuropharmacology 56(Suppl 1): 169-173.
14. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
15. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA (2003). Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28: 839-849.
16. Langlois X, te Riele P, Ashton D (2005). In vivo receptor occupancy profile of aripiprazole in rat brain. Soc Neurosci Abstracts 444: 3.
17. Laszy J, Laszlovszky I, Gyertyán I (2005). Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179: 567-575.
18. 3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors. Neuropharmacology 51: 168-172.
19. Loiseau F, Millan MJ (2009). Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur Neuropsychopharma-col 19: 23-33.
20. Merlo Pich E (2011). Translational approach to dopamine D3 receptor: from mechanism of action to clinical studies. Neuropsychopharmacology 36: S13.
21. Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM et al (2010). 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 53: 374-391.
22. Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D et al (2007). Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100: 1047-1061.
23. Mogg K, Bradley BP (2002). Selective processing of smoking-related cues in smokers: manipulation of deprivation level and comparison of three measures of processing bias. J Psychophar-macol 16: 385-392.
24. Mogg K, Bradley BP, Field M, De Houwer J (2003). Eye movements to smoking-related pictures in smokers: relationship between attentional biases and implicit and explicit measures of stimulus valence. Addiction 98: 825-836.
25. Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25: 1-9.
26. Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994). Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91: 11721-11275.
27. O'Brien CP, Childress AR, Ehrman R, Robbins SJ (1998). Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 12: 15-22.
28. Perkins KA, Broge M, Gerlach D, Sanders M, Grobe JE, Cherry C et al (2002). Acute nicotine reinforcement, but not chronic tolerance, predicts withdrawal and relapse after quitting smoking. Health Psychol 21: 332-339.
29. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (\+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63: 782-793.
30. Read KD, Braggio S (2010). Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6: 337-344.
31. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
32. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al (2010). Imaging dopamine D(3) receptors in the human brain with positron emission tomography, [(11)C] PHNO, and a selective D(3) receptor antagonist. Biol Psychiatry 68: 392-399.
33. Staley JK, Mash DC (1996). Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16: 6100-6106.
34. Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I, McGonigle P (2000). Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295: 1223-1231.
35. Surmeier DJ, Ding J, Day. M, Wang Z, Shen W (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30: 228-235.
36. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009). Imaging dopamine's role in drug abuse and addiction. Neuropharmacol-ogy 56(Suppl 1): 3-8.
37. Waters AJ, Shiffman S, Bradley BP, Mogg K (2003). Attentional shifts to smoking cues in smokers. Addiction 98: 1409-1417.
38. Zack M, Belsito L, Scher R, Eissenberg T, Corrigall WA (2001). Effects of abstinence and smoking on information processing in adolescent smokers. Psychopharmacology (Berl) 153: 249-257.